Clinical trials: Alzheimer's Type Dementia
Diabetes, Alzheimer Disease
The Diabetes Prevention Program Outcomes Study AD/ADRD Project
The DPPOS AD/ADRD project will address the overarching question: What are the determinants and the nature of cognitive impairment among persons with pre-diabetes (PreD) and type 2 diabetes (T2D), who are a high-risk group for…
- Conditions
- Diabetes, Alzheimer Disease, Dementia, Vascular, Dementia
- Trial name
- DPPOS-4 (NCT05704309)
- Where
- 27 sites in United States
- Volunteers
- 1,976 people, healthy volunteers welcome
- Sponsor
- Marinella Temprosa
Alzheimer Dementia, Alzheimer's Disease
Association of Cognition With Functional Mobility in People With Alzheimer's Disease
This study aimed to investigate relationship between cognitive function and functional mobility in Alzheimer's disease.
- Conditions
- Alzheimer Dementia, Alzheimer's Disease, Dementia, Alzheimer Type
- Trial name
- NCT05113732
- Where
- Turkey (Türkiye)
- Volunteers
- 64 people
- Sponsor
- Istanbul University - Cerrahpasa
Agitation
Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type
The primary objective of this study is to evaluate the efficacy of DMTS on frequency and severity of agitation associated with dementia of the Alzheimer's type, compared with placebo.
- Trial name
- NCT06052254
- Testing
- 12 cm2 - 2 Active DMTS Patches
- Where
- 8 sites in United States
- Volunteers
- 150 people
- Sponsor
- Teikoku Pharma USA, Inc.
Alzheimer Disease, Cognitive Impairment, Mild
Comparing Smartphone Technology and a Memory Strategy on Improving Prospective Memory in Alzheimer's Disease
Alzheimer's disease is a debilitating condition for patients and their caregivers marked by hallmark cognitive symptoms (e.g., memory loss) as well as an impact on quality of life.
- Conditions
- Alzheimer Disease, Cognitive Impairment, Mild, Dementia, Mild
- Trial name
- NCT03384043
- Testing
- Smartphone Personal Assistant, Implementation Intention
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Baylor University
Alzheimer's Disease
Nefiracetam in the Treatment of Alzheimer's Disease
Some of the thinking difficulties of Alzheimer's patients may be due to a deficiency in a brain chemical called acetylcholine, which helps transmit messages between nerve cells.
- Trial name
- NCT00001933
- Testing
- Nefiracetam
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Alzheimer Disease
Far Infrared Treatment for Alzheimer's Disease
Alzheimer's disease is a progressive and fatal brain disease. This study will investigate the use of far infrared radiation treatment for the disease.
- Trial name
- NCT00599469
- Testing
- Far Infrared Radiation (5μm to 20μm wavelength)
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- GAAD Medical Research Institute Inc.
Alzheimer's Disease
TNF-Alpha Inhibition for Treatment of Alzheimer's Disease
It is widely believed that inflammation contributes to the pathogenesis of AD. TNF has been implicated in both AD and neurological inflammation. Anti-TNF therapy is therefore surmised to be of potential benefit for treating AD.
- Trial name
- NCT00203320
- Testing
- etanercept given by perispinal administration
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Tobinick, Edward Lewis, M.D.
Alzheimer Disease, Dementia
Development of NIC5-15 in the Treatment of Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of NIC5-15in the treatment of Alzheimer's Disease.
- Trial name
- NCT00470418
- Testing
- NIC5-15
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- VA Office of Research and Development
Alzheimer Disease
A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease
The purpose of this study is to evaluate the safety and effectiveness of galantamine hydrobromide in patients with Alzheimer's disease who have not received or have not responded to treatment with medication similar to…
- Trial name
- NCT00297362
- Testing
- Galantamine hydrobromide
- Volunteers
- 344 people
- Sponsor
- Janssen Cilag Pharmaceutica S.A.C.I., Greece
Alzheimer's Disease
A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.
This was a multicenter, prospective, phase IV study evaluating safety, tolerability and effectiveness of rivastigmine 27 mg -15 cm^2 transdermal patch prescribed in patients with severe dementia of the Alzheimer's type as per…
- Trial name
- NCT02989402
- Testing
- Rivastigmine
- Where
- 9 sites in India
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Dementia, Alzheimer Type
TRx0014 in Patients With Mild or Moderate Alzheimer's Disease
The primary objective of the study is to investigate the effects of oral TRx0014 at three doses (30, 60 and 100 mg tid) compared with placebo on cognitive ability in patients with mild or moderate dementia of the Alzheimer type.
- Trial name
- NCT00515333
- Testing
- TRx0014
- Volunteers
- 323 people
- Sponsor
- TauRx Therapeutics Ltd
Agitation Associated With Alzheimer's Disease, Alzheimer's Type
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
To follow-up on the safety of subjects who were previously treated in a double-blind trial of brexpiprazole.
- Conditions
- Agitation Associated With Alzheimer's Disease, Alzheimer's Type, Mental Disorder, Nervous System Diseases
- Trial name
- NCT02192554
- Where
- 84 sites in United States, Bulgaria and 10 more
- Volunteers
- 450 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alzheimer's Type Dementia
Intensive Instruction on the Use of Aricept
The purpose of this study is to examine the influence of the instruction on the use of Aricept with educational brochure on the 48-week medication persistence and to assess the reasons for discontinuation.
- Trial name
- NCT01972204
- Testing
- Intensive adherence instruction, Control
- Where
- Japan
- Volunteers
- 125 people
- Sponsor
- Mirai Iryo Research Center, Inc.
Alzheimer's Disease
TNF-Alpha Inhibition for Treatment of Alzheimer's Disease
It is widely believed that inflammation contributes to the pathogenesis of AD. TNF has been implicated in both AD and neurological inflammation. Anti-TNF therapy is therefore surmised to be of potential benefit for treating AD.
- Trial name
- NCT00203359
- Testing
- etanercept given by perispinal administration
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Tobinick, Edward Lewis, M.D.
Dementia, Alzheimer Type
Memantine Versus Donepezil in Early Stages of Alzheimer's Disease
It is well known that in the brain of the patients with Alzheimer's disease there is a glutamatergic hyperstimulation leading to neuronal death. Memantine is a low affinity antagonist of NMDA glutamate receptors.
- Trial name
- NCT00505167
- Testing
- Memantine, Donepezil
- Where
- 3 sites in Spain
- Volunteers
- 64 people
- Sponsor
- Hospital Miguel Servet